General Counsel
Neumora Therapeutics, Inc. (NMRA)Equibles does not estimate personal net worth.
Get an email with a short summary when Neumora Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get NMRA alertsJason Duncan is recorded as General Counsel at Neumora Therapeutics, Inc. (NMRA) since February 14, 2025. Neumora Therapeutics, Inc. reported in an 8-K filed February 13, 2025 that Jason Duncan was appointed Chief Legal and Administrative Officer, effective February 14, 2025. The proxy statement of Neumora Therapeutics, Inc. reports total compensation of $4,119,980 for Jason Duncan in fiscal 2023, including a base salary of $26,250. Jason Duncan has spoken on 1 investor event across 1 company, most recently for Neumora Therapeutics, Inc. on May 27, 2026. Neumora Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Neumora Therapeutics, Inc. includes Joshua Pinto (CEO and Board Member), Paul L. Berns (CEO, Chairman and Board Member), Michael Milligan (CFO) and 7 others.
“Jason Duncan will serve as Chief Legal and Administrative Officer”
“The inspector of election has informed me that each of the named nominees for director have been duly elected. The selection of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026 has been ratified.”
2025-02-14–present
Proxy statement
Start not stated–present
Last confirmed April 17, 2026
Biotechnology · Healthcare
General Counsel
2025-02-14–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Neumora Therapeutics, Inc. (NMRA) | Chief Legal Officer | $26,250 | $4,119,980 |
